KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Abbott Laboratories (ABT) over the last 17 years, with Q3 2025 value amounting to -$457.0 million.

  • Abbott Laboratories' Cash from Investing Activities rose 2306.4% to -$457.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.4 billion, marking a year-over-year decrease of 344.08%. This contributed to the annual value of -$2.3 billion for FY2024, which is 2537.5% up from last year.
  • Latest data reveals that Abbott Laboratories reported Cash from Investing Activities of -$457.0 million as of Q3 2025, which was up 2306.4% from -$582.0 million recorded in Q2 2025.
  • Abbott Laboratories' Cash from Investing Activities' 5-year high stood at -$264.0 million during Q2 2021, with a 5-year trough of -$1.2 billion in Q2 2023.
  • Its 5-year average for Cash from Investing Activities is -$564.6 million, with a median of -$484.0 million in 2022.
  • Per our database at Business Quant, Abbott Laboratories' Cash from Investing Activities crashed by 35946.97% in 2023 and then soared by 6265.46% in 2024.
  • Abbott Laboratories' Cash from Investing Activities (Quarter) stood at -$671.0 million in 2021, then grew by 5.81% to -$632.0 million in 2022, then tumbled by 30.38% to -$824.0 million in 2023, then decreased by 5.1% to -$866.0 million in 2024, then surged by 47.23% to -$457.0 million in 2025.
  • Its Cash from Investing Activities was -$457.0 million in Q3 2025, compared to -$582.0 million in Q2 2025 and -$470.0 million in Q1 2025.